Thomas K. Henthorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas K. Henthorn has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Jost Klawitter
University of Colorado Denver
4 shared publicationsUwe Christians
University of Colorado Denver School of Medicine
4 shared publications- Ashley Brooks-Russell
Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
3 shared publications Cristina Sempio
University of Colorado Denver School of Medicine
3 shared publications- George Sam Wang
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora
3 shared publications - Michael J. Kosnett
Department of Environmental and Occupational Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado
3 shared publications
Latest Publications
- 1 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 739-750
Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model
Methadone is a utilitarian opioid with growing use for anesthesia and postoperative pain. Methadone pharmacokinetic models have evolved over time; however, there is no comprehensive population pharmacokinetic model. This investigation developed a population model for R (−)‐ and S (+)‐enantiomers of methadone and the primary metabolite 2‐ethyl‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine (EDDP) in plasma and urine, incorporating enantiomeric disposition, metabolism, genetics, renal elimination, and frequent and long‐duration sampling, to adequately describe both distribution and elimination. In this secondary analysis of previously obtained data from 64 adults sampled for 96 hours, a compartmental model utilizing eight distinct measurement categories of drug and metabolite concentration that unified enantiomer kinetics was developed using nonlinear mixed effects techniques. Potential model covariates for weight, race, sex, CYP2B6 genetics, and CYP2C19 genetics were tested. The final unified three‐compartment population model accounted for significant and systematic enantiomer‐specific differences in volumes of distribution, intercompartmental and elimination clearances between R (−)‐ and S (+)‐methadone, by estimating S (+)/ R (−) ratios. The model incorporated weight and CYP2B6 genotype but not CYP2C19 genotype, sex or race as covariates. Intersubject variability was consistent with that of other intravenous opioids. S (+)/ R (−) ratios were consistent with known enantiomeric differences in α 1 ‐acid glycoprotein binding and in vitro biotransformation, and disposition was explainable by enantiomeric restrictive plasma protein binding effects on drug distribution, pharmacokinetic flow, and intrinsic hepatic clearance (CYP2B6‐catalyzed metabolism). The population model may be applicable to pharmacokinetically guided intravenous methadone dosing and CYP2B6‐mediated drug interactions in perioperative and critical care settings.
- 1 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 739-750
Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model
Methadone is a utilitarian opioid with growing use for anesthesia and postoperative pain. Methadone pharmacokinetic models have evolved over time; however, there is no comprehensive population pharmacokinetic model. This investigation developed a population model for R (−)‐ and S (+)‐enantiomers of methadone and the primary metabolite 2‐ethyl‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine (EDDP) in plasma and urine, incorporating enantiomeric disposition, metabolism, genetics, renal elimination, and frequent and long‐duration sampling, to adequately describe both distribution and elimination. In this secondary analysis of previously obtained data from 64 adults sampled for 96 hours, a compartmental model utilizing eight distinct measurement categories of drug and metabolite concentration that unified enantiomer kinetics was developed using nonlinear mixed effects techniques. Potential model covariates for weight, race, sex, CYP2B6 genetics, and CYP2C19 genetics were tested. The final unified three‐compartment population model accounted for significant and systematic enantiomer‐specific differences in volumes of distribution, intercompartmental and elimination clearances between R (−)‐ and S (+)‐methadone, by estimating S (+)/ R (−) ratios. The model incorporated weight and CYP2B6 genotype but not CYP2C19 genotype, sex or race as covariates. Intersubject variability was consistent with that of other intravenous opioids. S (+)/ R (−) ratios were consistent with known enantiomeric differences in α 1 ‐acid glycoprotein binding and in vitro biotransformation, and disposition was explainable by enantiomeric restrictive plasma protein binding effects on drug distribution, pharmacokinetic flow, and intrinsic hepatic clearance (CYP2B6‐catalyzed metabolism). The population model may be applicable to pharmacokinetically guided intravenous methadone dosing and CYP2B6‐mediated drug interactions in perioperative and critical care settings.
- Open Access
- 23 May 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 672-680
Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users
Background: Unusually high variability in blood Δ9-tetrahydrocannabinol (THC) concentrations have been observed in subjects inhaling similar cannabis products over similar time periods when consumption is ad libitum. This makes simple gravimetric dose estimation a poor predictor of THC exposure. Population pharmacokinetic analyses of blood THC concentration versus time data are routinely used to estimate pharmacokinetic parameters. The aim of this study was to estimate the inhaled dose of THC in occasional and daily users of high potency market cannabis. Methods: Blood THC concentrations were measured for 135 minutes from 29 participants who either smoked high concentration flower or inhaled concentrates ad libitum during a 15-minute session. Frequent blood samples were obtained over the following 135 minutes. Results: The estimated central and rapidly equilibrating volumes of distribution of a 3-compartment model were 19.9 ± 1.2 and 51.6 ± 4.7 L whereas the intercompartmental clearances were 1.65 ± 0.14 and 1.75 ± 0.10 L/min, respectively. Covariate-adjusted analysis revealed that the estimated inhaled THC dose was considerably less among occasional users compared with daily users. Conclusions: Three-compartment pharmacokinetics of THC did not differ among the 3 user groups, and the early phase (first 135 minutes postinception of inhalation) kinetics were similar to those previously described after smoking low potency cannabis products. Therefore, inhaled THC dose can be estimated from pharmacokinetic data and covariate-driven adjustments can be used to estimate THC doses, based on the participant cannabis usage pattern (occasional versus daily), improving the accuracy of THC exposure estimates compared with those derived from weighed THC content alone.
- 23 May 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 672-680
Open AccessDose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users
Background: Unusually high variability in blood Δ9-tetrahydrocannabinol (THC) concentrations have been observed in subjects inhaling similar cannabis products over similar time periods when consumption is ad libitum. This makes simple gravimetric dose estimation a poor predictor of THC exposure. Population pharmacokinetic analyses of blood THC concentration versus time data are routinely used to estimate pharmacokinetic parameters. The aim of this study was to estimate the inhaled dose of THC in occasional and daily users of high potency market cannabis. Methods: Blood THC concentrations were measured for 135 minutes from 29 participants who either smoked high concentration flower or inhaled concentrates ad libitum during a 15-minute session. Frequent blood samples were obtained over the following 135 minutes. Results: The estimated central and rapidly equilibrating volumes of distribution of a 3-compartment model were 19.9 ± 1.2 and 51.6 ± 4.7 L whereas the intercompartmental clearances were 1.65 ± 0.14 and 1.75 ± 0.10 L/min, respectively. Covariate-adjusted analysis revealed that the estimated inhaled THC dose was considerably less among occasional users compared with daily users. Conclusions: Three-compartment pharmacokinetics of THC did not differ among the 3 user groups, and the early phase (first 135 minutes postinception of inhalation) kinetics were similar to those previously described after smoking low potency cannabis products. Therefore, inhaled THC dose can be estimated from pharmacokinetic data and covariate-driven adjustments can be used to estimate THC doses, based on the participant cannabis usage pattern (occasional versus daily), improving the accuracy of THC exposure estimates compared with those derived from weighed THC content alone.
- 7 May 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 140 (6) , 1059-1061
Reversal for Respiratory Depression: Let’s Take a Breath!
ANESTHESIOLOGY is the highest-impact, peer-reviewed medical journal that publishes trusted evidence that transforms the practice of perioperative,
- 7 May 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 140 (6) , 1059-1061
Reversal for Respiratory Depression: Let’s Take a Breath!
ANESTHESIOLOGY is the highest-impact, peer-reviewed medical journal that publishes trusted evidence that transforms the practice of perioperative,
- Open Access
- 31 January 2024
- Published by Wiley
Urinary Clearance of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH): A Detailed Pharmacokinetic Analysis
Background. Urine is a common matrix for screening for cannabis use. Urine assays typically measure total THCCOOH concentrations after hydrolysis cleaves the glucuronide. Urine THCCOOH concentration is adjusted by urine creatinine concentration or specific gravity, to account for variable hydration states. Therefore, we performed a population pharmacokinetic analysis of the urinary THCCOOH excretion, urinary flow rate, and creatinine excretion rate data. Methods. Urine was obtained over 168 hours from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on two occasions. Samples were analyzed for THCCOOH concentration by GC/MS and volume, time and creatinine concentration measured. A population pharmacokinetic model of the urinary clearance of THCCOOH was created from these data and potential covariates of urine creatinine concentration and urine creatinine excretion rate were assessed. Results. Elimination clearance of THCCOOH was estimated as 0.104 ± 0.088 L/min and its urinary clearance was 0.0022 ± 0.0015 L/min. Total urine excretion of THCCOOH was estimated a 2.3%. Urine flow rate and urine creatinine concentrations were significantly correlated, r2 0.35. Creatinine excretion rate was 129.6 ± 71.0 mL/min and the intra-subject variability was 31-52% (SD%) during the week. Urinary creatinine excretion rate was a significant covariate for the urinary clearance of THCCOOH. Conclusions. Creatinine Clearance is a significant covariate for urinary THCCOOH clearance. Only 2-3% of bioavailable THC is excreted as THCCOOH and THCCOO-glucuronide via the urine. Correction of urine drug and/or metabolite concentration with urine creatinine concentration or specific gravity may be more problematic than previously appreciated.
- 31 January 2024
- Published by Wiley
Open AccessUrinary Clearance of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH): A Detailed Pharmacokinetic Analysis
Background. Urine is a common matrix for screening for cannabis use. Urine assays typically measure total THCCOOH concentrations after hydrolysis cleaves the glucuronide. Urine THCCOOH concentration is adjusted by urine creatinine concentration or specific gravity, to account for variable hydration states. Therefore, we performed a population pharmacokinetic analysis of the urinary THCCOOH excretion, urinary flow rate, and creatinine excretion rate data. Methods. Urine was obtained over 168 hours from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on two occasions. Samples were analyzed for THCCOOH concentration by GC/MS and volume, time and creatinine concentration measured. A population pharmacokinetic model of the urinary clearance of THCCOOH was created from these data and potential covariates of urine creatinine concentration and urine creatinine excretion rate were assessed. Results. Elimination clearance of THCCOOH was estimated as 0.104 ± 0.088 L/min and its urinary clearance was 0.0022 ± 0.0015 L/min. Total urine excretion of THCCOOH was estimated a 2.3%. Urine flow rate and urine creatinine concentrations were significantly correlated, r2 0.35. Creatinine excretion rate was 129.6 ± 71.0 mL/min and the intra-subject variability was 31-52% (SD%) during the week. Urinary creatinine excretion rate was a significant covariate for the urinary clearance of THCCOOH. Conclusions. Creatinine Clearance is a significant covariate for urinary THCCOOH clearance. Only 2-3% of bioavailable THC is excreted as THCCOOH and THCCOO-glucuronide via the urine. Correction of urine drug and/or metabolite concentration with urine creatinine concentration or specific gravity may be more problematic than previously appreciated.
- 4 May 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (5) , 355-362
Blood cannabinoid molar metabolite ratios are superior to blood THC as an indicator of recent cannabis smoking
Cannabis use is a growing concern in transportation and workplace incidents. Because Δ9-tetrahydrocannabinol is detectable after acute psychoactive effects have resolved, it has limitations as an indicator of recent usage or potential impairment. In an observational study of driving and psychomotor performance, we measured whole blood Δ9-tetrahydrocannabinol plus its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol by liquid chromatography with tandem mass spectrometry at baseline and 30 min after starting a 15-minute interval of smoking cannabis in 24 occasional and 32 daily cannabis smokers. We calculated two blood cannabinoid molar metabolite ratios: 1) [Δ9-tetrahydrocannabinol] to [11-nor-9-carboxy-Δ9-tetrahydrocannabinol] and 2) ([Δ9-tetrahydrocannabinol] + [11-hydroxy-Δ9-tetrahydrocannabinol]) to [11-nor-9-carboxy-Δ9-tetrahydrocannabinol]. We compared these to blood [Δ9-tetrahydrocannabinol] alone as indicators of recent cannabis smoking. Median Δ9-tetrahydrocannabinol concentrations increased from 0 ( 0.38). By comparison, a cut-point for Δ9-tetrahydrocannabinol of 5.3 µg/L yielded 88% specificity, 73% sensitivity, and 80% accuracy. In occasional and daily users, the blood cannabinoid molar metabolite ratios were superior to whole blood Δ9-tetrahydrocannabinol as indicators of recent cannabis smoking. We recommend measurement and reporting of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, and their molar metabolite ratios in forensic and safety investigations.
- 4 May 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (5) , 355-362
Blood cannabinoid molar metabolite ratios are superior to blood THC as an indicator of recent cannabis smoking
Cannabis use is a growing concern in transportation and workplace incidents. Because Δ9-tetrahydrocannabinol is detectable after acute psychoactive effects have resolved, it has limitations as an indicator of recent usage or potential impairment. In an observational study of driving and psychomotor performance, we measured whole blood Δ9-tetrahydrocannabinol plus its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol by liquid chromatography with tandem mass spectrometry at baseline and 30 min after starting a 15-minute interval of smoking cannabis in 24 occasional and 32 daily cannabis smokers. We calculated two blood cannabinoid molar metabolite ratios: 1) [Δ9-tetrahydrocannabinol] to [11-nor-9-carboxy-Δ9-tetrahydrocannabinol] and 2) ([Δ9-tetrahydrocannabinol] + [11-hydroxy-Δ9-tetrahydrocannabinol]) to [11-nor-9-carboxy-Δ9-tetrahydrocannabinol]. We compared these to blood [Δ9-tetrahydrocannabinol] alone as indicators of recent cannabis smoking. Median Δ9-tetrahydrocannabinol concentrations increased from 0 ( 0.38). By comparison, a cut-point for Δ9-tetrahydrocannabinol of 5.3 µg/L yielded 88% specificity, 73% sensitivity, and 80% accuracy. In occasional and daily users, the blood cannabinoid molar metabolite ratios were superior to whole blood Δ9-tetrahydrocannabinol as indicators of recent cannabis smoking. We recommend measurement and reporting of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, and their molar metabolite ratios in forensic and safety investigations.
- 20 March 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (5) , 363-369
The minor cannabinoid cannabigerol (CBG) is a highly specific blood biomarker of recent cannabis smoking
The determination of recent cannabis use is of forensic interest in the investigation of automotive crashes, workplace incidents and other mishaps. Because Δ9-tetrahydrocannabinol may persist in bl...
- 20 March 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (5) , 363-369
The minor cannabinoid cannabigerol (CBG) is a highly specific blood biomarker of recent cannabis smoking
The determination of recent cannabis use is of forensic interest in the investigation of automotive crashes, workplace incidents and other mishaps. Because Δ9-tetrahydrocannabinol may persist in bl...
- 1 April 2022
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (8) , 1368-1376
Urinary clearance of 11‐nor‐9‐carboxy‐Δ9‐tetrahydrocannabinol: A detailed pharmacokinetic analysis
Urine is a common matrix for screening for cannabis use. Urine assays typically measure total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) concentrations after hydrolysis cleaves the glucuronide. Urine THCCOOH concentration is adjusted by urine creatinine concentration or specific gravity, to account for variable hydration states. Therefore, we performed a population pharmacokinetic analysis of the urinary THCCOOH excretion, urinary flow rate, and creatinine excretion rate data. Urine was obtained over 168 h from six subjects who smoked low- (15.8 mg) and high-dose (33.8 mg) Delta(9)-tetrahydrocannabinol (THC) cigarettes on two occasions. Samples were analyzed for THCCOOH concentration by gas chromatography-mass spectrometry (GC-MS) and volume, time, and creatinine concentration measured. A population pharmacokinetic model of the urinary clearance of THCCOOH was created from these data, and potential covariates of urine creatinine concentration and urine creatinine excretion rate were assessed. Elimination clearance of THCCOOH was estimated as 0.104 +/- 0.088 L/min, and its urinary clearance was 0.0022 +/- 0.0015 L/min. Total urine excretion of THCCOOH was estimated at 2.3%. Urine flow rate and urine creatinine concentrations were significantly correlated, r(2) = 0.35. Creatinine excretion rate was 129.6 +/- 71.0 ml/min, and the intrasubject variability was 31%-52% (SD %) during the week. Urinary creatinine excretion rate was a significant covariate for the urinary clearance of THCCOOH. Creatinine clearance is a significant covariate for urinary THCCOOH clearance. Only 2%-3% of bioavailable THC is excreted as THCCOOH and THCCOO-glucuronide via the urine. Correction of urine drug and/or metabolite concentration with urine creatinine concentration or specific gravity may be more problematic than previously appreciated.
- 1 April 2022
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (8) , 1368-1376
Urinary clearance of 11‐nor‐9‐carboxy‐Δ9‐tetrahydrocannabinol: A detailed pharmacokinetic analysis
Urine is a common matrix for screening for cannabis use. Urine assays typically measure total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) concentrations after hydrolysis cleaves the glucuronide. Urine THCCOOH concentration is adjusted by urine creatinine concentration or specific gravity, to account for variable hydration states. Therefore, we performed a population pharmacokinetic analysis of the urinary THCCOOH excretion, urinary flow rate, and creatinine excretion rate data. Urine was obtained over 168 h from six subjects who smoked low- (15.8 mg) and high-dose (33.8 mg) Delta(9)-tetrahydrocannabinol (THC) cigarettes on two occasions. Samples were analyzed for THCCOOH concentration by gas chromatography-mass spectrometry (GC-MS) and volume, time, and creatinine concentration measured. A population pharmacokinetic model of the urinary clearance of THCCOOH was created from these data, and potential covariates of urine creatinine concentration and urine creatinine excretion rate were assessed. Elimination clearance of THCCOOH was estimated as 0.104 +/- 0.088 L/min, and its urinary clearance was 0.0022 +/- 0.0015 L/min. Total urine excretion of THCCOOH was estimated at 2.3%. Urine flow rate and urine creatinine concentrations were significantly correlated, r(2) = 0.35. Creatinine excretion rate was 129.6 +/- 71.0 ml/min, and the intrasubject variability was 31%-52% (SD %) during the week. Urinary creatinine excretion rate was a significant covariate for the urinary clearance of THCCOOH. Creatinine clearance is a significant covariate for urinary THCCOOH clearance. Only 2%-3% of bioavailable THC is excreted as THCCOOH and THCCOO-glucuronide via the urine. Correction of urine drug and/or metabolite concentration with urine creatinine concentration or specific gravity may be more problematic than previously appreciated.
- 29 December 2021
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 136 (2) , 258-260
Elimination Clearance of Dexmedetomidine: Cross-examining What the Data Say
- 29 December 2021
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 136 (2) , 258-260
Elimination Clearance of Dexmedetomidine: Cross-examining What the Data Say
- 1 August 2021
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 43 (4) , 536-545
Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado
Background: Self-report questionnaires, weighing products consumed, and Δ9-tetrahydrocannabinol (THC) biomarkers are established techniques for estimating cannabis exposure. Population pharmacokinetic modeling of plasma THC and metabolite concentrations by incorporating self-reported and weighed products as covariates could improve estimates of THC exposure in regular cannabis users. Methods: In this naturalistic study, blood samples were obtained from 36 regular smokers of cannabis for analysis of THC and its 2 metabolites at 4 time points: recruitment and during an experimental mobile laboratory assessment that included 3 time points: before, immediately after, and 1 hour after ad libitum legal market flower use. These data were analyzed using an established model of population pharmacokinetics developed from laboratory-controlled cannabis administration data. Elimination and metabolite production clearances were estimated for each subject as well as their daily THC doses and the dose consumed during the ad libitum event. Results: A statistically significant correlation existed between the daily THC dose estimated by self-report questionnaire and population pharmacokinetic modeling (correlation coefficient = 0.79, P < 0.05) between the weighed cannabis smoked ad libitum and that estimated by population pharmacokinetic modeling (correlation coefficient = 0.71, P < 0.05). Conclusion: Inclusion of self-reported questionnaire data of THC consumption improved pharmacokinetic model–derived estimates based on measured THC and metabolite concentrations. In addition, the pharmacokinetic-derived dose estimates for the ad libitum smoking event underestimated the THC consumption compared with the weighed amount smoked. Thus, the subjects in this study, who smoked ad libitum and used cannabis products with high concentrations of THC, were less efficient (lower bioavailability) compared with computer-paced smokers of low potency, NIDA cannabis in a laboratory setting.
- 1 August 2021
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 43 (4) , 536-545
Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado
Background: Self-report questionnaires, weighing products consumed, and Δ9-tetrahydrocannabinol (THC) biomarkers are established techniques for estimating cannabis exposure. Population pharmacokinetic modeling of plasma THC and metabolite concentrations by incorporating self-reported and weighed products as covariates could improve estimates of THC exposure in regular cannabis users. Methods: In this naturalistic study, blood samples were obtained from 36 regular smokers of cannabis for analysis of THC and its 2 metabolites at 4 time points: recruitment and during an experimental mobile laboratory assessment that included 3 time points: before, immediately after, and 1 hour after ad libitum legal market flower use. These data were analyzed using an established model of population pharmacokinetics developed from laboratory-controlled cannabis administration data. Elimination and metabolite production clearances were estimated for each subject as well as their daily THC doses and the dose consumed during the ad libitum event. Results: A statistically significant correlation existed between the daily THC dose estimated by self-report questionnaire and population pharmacokinetic modeling (correlation coefficient = 0.79, P < 0.05) between the weighed cannabis smoked ad libitum and that estimated by population pharmacokinetic modeling (correlation coefficient = 0.71, P < 0.05). Conclusion: Inclusion of self-reported questionnaire data of THC consumption improved pharmacokinetic model–derived estimates based on measured THC and metabolite concentrations. In addition, the pharmacokinetic-derived dose estimates for the ad libitum smoking event underestimated the THC consumption compared with the weighed amount smoked. Thus, the subjects in this study, who smoked ad libitum and used cannabis products with high concentrations of THC, were less efficient (lower bioavailability) compared with computer-paced smokers of low potency, NIDA cannabis in a laboratory setting.
- 5 May 2021
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 127 (1) , 1-2
How relevant is stereoselectivity to the side-effects of ketamine?
- 5 May 2021
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 127 (1) , 1-2
How relevant is stereoselectivity to the side-effects of ketamine?